about
Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancerEffect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcomePhase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.Hypoxia inducible factor-1alpha as a cancer drug targetHIF-1 regulation: not so easy come, easy goPhosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancerMolecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signalingIncreased intracellular Ca2+ signaling caused by the antitumor agent helenalin and its analoguesDevelopment of sulfonamide AKT PH domain inhibitors.Novel Water-Soluble Diorganyl Tellurides with Thiol Peroxidase and Antioxidant Activity.Redox potential of human thioredoxin 1 and identification of a second dithiol/disulfide motif.Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1alpha using PX-478.Metabolite changes in HT-29 xenograft tumors following HIF-1alpha inhibition with PX-478 as studied by MR spectroscopy in vivo and ex vivo.The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasmaDiscovery of a novel class of AKT pleckstrin homology domain inhibitors.In Vivo Therapeutic Silencing of Hypoxia-Inducible Factor 1 Alpha (HIF-1α) Using Single-Walled Carbon Nanotubes Noncovalently Coated with siRNA.Molecular pharmacology and antitumor activity of PHT-427, a novel Akt/phosphatidylinositide-dependent protein kinase 1 pleckstrin homology domain inhibitor.Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM.In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT.Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma.The promise of patient-derived xenografts: the best laid plans of mice and menThe absence of mitochondrial thioredoxin 2 causes massive apoptosis, exencephaly, and early embryonic lethality in homozygous mice.The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenograftsMolecular pharmacology and antitumor activity of palmarumycin-based inhibitors of thioredoxin reductase.The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures.The skin and hair as surrogate tissues for measuring the target effect of inhibitors of phosphoinositide-3-kinase signalingAntitumor agent PX-12 inhibits HIF-1α protein levels through an Nrf2/PMF-1-mediated increase in spermidine/spermine acetyl transferase.IL-24 is expressed during wound repair and inhibits TGFalpha-induced migration and proliferation of keratinocytesHypoxia inducible factor as a cancer drug target.Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells.Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.Tumor Xenograft Response to Redox-Active Therapies Assessed by Magnetic Resonance Imaging Using a Thiol-Bearing DOTA Complex of Gadolinium.HNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer.The hypoxic inducible stress response as a target for cancer drug discovery.Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.Thioredoxin signaling as a target for cancer therapy.ERK5 signalling rescues intestinal epithelial turnover and tumour cell proliferation upon ERK1/2 abrogation.Hypoxia-associated factor, a novel E3-ubiquitin ligase, binds and ubiquitinates hypoxia-inducible factor 1alpha, leading to its oxygen-independent degradation.Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.
P50
Q24616197-BF502DDF-675C-46FB-A556-7AD5B359D45EQ27851703-636631CF-9723-4892-A0AD-E224A8487993Q27853224-C04172E0-27F1-4809-9623-B747A674180DQ28261521-5B3DA3D6-182B-4758-B4AC-F83EB0CA93ADQ28294862-B02D6980-12B8-4C85-8173-D8E346CD5985Q28472770-1CD4DA80-8F93-4F0A-B6D4-1C51FE082BB8Q28638664-507F1B97-DE29-4A78-AC6E-9F9DA6266CF2Q30040251-F7ECD1D5-D9EB-4534-9CFE-2A72F7AAC685Q30500090-38C873A5-D92A-4549-8D68-A594A1A2EB3BQ30664146-EC7025E8-1276-4D0A-80AB-251EE78663A5Q30950439-219613CC-DEF4-45F0-A382-3F62761F6A6AQ30992467-3D259D01-B190-4A89-8D05-91BB69D09332Q31009512-9E995FE5-478A-4BC5-8B47-636AD72A2196Q33233126-CAD56084-CCC2-4830-8F3B-296D0CF49CE2Q33369369-459BAC38-BDA0-40CF-9759-23564384A415Q33568871-90237261-B923-4A7A-B5C8-4D9B16662C96Q33722849-102CB0E7-DDC8-4A44-ABFB-F669236FD5A6Q33853600-647A5F0F-E652-4E9A-ACF0-33B552CD3E30Q34037704-6D491470-A2DE-4A4B-A798-5CFD6C38E8DEQ34345154-9DCF4D5A-CFC6-4F44-BAA3-194170BE79C3Q34443008-60315C17-FDB5-4A07-A597-4463F4D7EC59Q34463545-6FD47771-01DB-4BE6-ADDE-53C4B0DA14D1Q34524510-C5BE2B91-3BBC-494A-A123-708ED1F86625Q34619502-AE3F1C9A-61BC-4AA4-A555-56F1A0455342Q34674397-62454285-EF53-49E8-9865-04718C0FDABDQ34708815-D738DD2C-7B1C-4F3F-8A2B-CFE79698738BQ35022155-3E75B5F5-AF00-4D1B-9AEA-4FFBDB5C9C91Q35180316-5BCC5CEA-AD39-4BF0-9A43-C8CE776A819CQ35610688-F24BB5E0-563F-4805-B029-7BBCFC2BBDE3Q35883238-CECB0A34-CA0F-40D6-97DF-73D2BF7A2B96Q35949785-0F558DFD-A21C-4602-9883-76E3F52A713DQ36061797-0B722073-6544-4B7B-9C1E-31DEC6B1A2A2Q36475493-E364CFAE-F0CB-4C37-BD18-C8552DF8598FQ36557316-968852EB-226C-4074-BFBA-2CAE91720D6EQ36659868-85D30A38-774C-49ED-A176-418970F8B64DQ36870409-EF4B36C9-99F7-43D6-AD89-8810E7EF77DEQ36918817-ECAF6FDA-5D53-4E70-A9E2-1AA313B53181Q36994805-43CB571F-2E67-4D18-BF69-986814C7ACFCQ37036297-51CFFDB5-1299-47C6-8567-7ABE1B8F68C5Q37079820-32E0599E-87BF-4703-A184-E4D9365219D7
P50
name
Garth Powis
@en
Garth Powis
@nl
type
label
Garth Powis
@en
Garth Powis
@nl
prefLabel
Garth Powis
@en
Garth Powis
@nl